Objective: To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy on biochemical parameters, seizure control, and developmental/cognitive outcomes in children with pyridoxinedependent epilepsy (PDE) caused by antiquitin (ATQ) deficiency. Methods: In this observational study, seven children with confirmed ATQ deficiency were started on dietary lysine restriction with regular nutritional monitoring. Biochemical outcomes were evaluated using pipecolic acid and α-aminoadipic semialdehyde (AASA) levels in body fluids; developmental/cognitive outcomes were evaluated using age-appropriate tests and parental observations. Results: Lysine restriction was well tolerated with good compliance; no adverse events were reported. Reduction in biomarker levels (measurement of the last value before and first value after initiation of dietary lysine restriction) ranged from 20 to 67% for plasma pipecolic acid, 13 to 72% for urinary AASA, 45% for plasma AASA and 42% for plasma P6C. For the 1 patient in whom data were available and who showed clinical deterioration upon interruption of diet, cerebrospinal fluid levels decreased by 87.2% for pipecolic acid and 81.7% for AASA. Improvement in age-appropriate skills was observed in 4 out of 5 patients showing pre-diet delays, and seizure control was maintained or improved in 6 out 7 children. Conclusions: This observational study provides Level 4 evidence that lysine restriction is well tolerated with significant decrease of potentially neurotoxic biomarkers in different body compartments, and with the potential to improve developmental outcomes in children with PDE caused by ATQ deficiency. To generate a strong level of evidence before this potentially burdensome dietary therapy becomes the mainstay treatment, we have established: an international PDE consortium to conduct future studies with an all-inclusive integrated study design; a website containing up-to-date information on PDE; a methodological toolbox; and an online registry to facilitate the participation of interested physicians, scientists, and families in PDE research.
Introduction
Pyridoxine-dependent epilepsy (PDE) is an autosomal recessive epileptic encephalopathy characterized by a therapeutic response to pharmacological dosages of pyridoxine and resistance to conventional antiepileptic treatment [1] . Recently, the underlying genetic defect was identified as deficiency of antiquitin (ATQ) (α-aminoadipic semialdehyde dehydrogenase, ALDH7A1), an enzyme that facilitates cerebral lysine catabolism (MIM# 266100) [2] . Folinic acid-responsive seizures are also caused by mutations in this gene [3] . ATQ deficiency results in accumulation of chemical substrates arising from lysine degradation proximal to the deficient enzyme activity including α-aminoadipic semialdehyde (AASA), its cyclic equivalent P6C, and pipecolic acid. Inactivation of 5′ pyridoxal phosphate (PLP) via chemical reaction with P6C is a pathophysiological mechanism of pyridoxine dependency. While treatment with pyridoxine compensates chemical PLP inactivation, the accumulation of substrates from lysine degradation is not sufficiently reduced (Fig. 1) . These potentially neurotoxic compounds could explain for the limited efficacy of pyridoxine, as 75-80% of patients suffer developmental delay or intellectual disability (IQb 70) despite seizure control [4, 5] .
Standard treatment for inborn errors of metabolism affecting catabolic pathways of essential amino acids consists of substrate reduction to the deficient enzyme activity by dietary modification. Thus, for ATQ deficiency, dietary lysine restriction can reduce the accumulation of lysinederived substrates and improve cerebral function (neurodevelopment, cognition, behavior). Based on this rationale, we initiated an open-label observational study to test the effectiveness and safety of dietary lysine restriction as an adjunct to pyridoxine therapy on chemical biomarkers, seizure control, and developmental or cognitive outcomes in 7 children with confirmed ATQ deficiency.
Patients and methods

Study setting and inclusion criteria
The patients in this report were cared for at three academic medical centers (Hannover, Germany; Vancouver, Canada; and Denver, USA) between 2008 and 2012. Patients were screened according to the following eligibility criteria: age 0 to 18 years, genetically and biochemically confirmed ATQ deficiency, clinically followed at one of the three study sites, and parents or family willing to provide informed consent. Of the 9 consecutive patients with confirmed ATQ deficiency at the 2 sites during the recruitment period [2008] [2009] [2010] [2011] , 7 were enrolled in the study. Reasons for exclusion were: age >18 years (n =1), parents declined (n=1). All participating clinicians had been actively involved in international workshops and meetings held in Vancouver, Canada and Geneva, Switzerland during the period 2009-2011, to develop consensus on diagnosis and treatment of ATQ deficiency [5] , and a protocol to study the effects of dietary lysine restriction.
Standard treatment
All patients were treated according to existing recommendations summarized by Stockler et al. [6] . During dietary treatment, patients received pyridoxine dosages between 1 and 30 mg/kg/day PO. In patient #2, higher doses of pyridoxine were prescribed prior to starting the diet, due to inadequate seizure control. Folinic acid, clobazam, and/or phenobarbital were prescribed to individual patients if the pyridoxine alone was not effective in controlling seizures.
Lysine-restricted diet
Diet prescriptions were based on the Kölker and Ross guidelines for Glutaric Aciduria type I, another inborn error of metabolism involving compromised degradation of lysine [7] : Lysine was prescribed at 70-100 mg/kg/day, 45-80 mg/kg/day and 20-45 mg/kg/day to children aged respectively less than 1 year, between 1 and 7 years, and above 7 years. In patients #6 and #7, lysine was restricted in early infancy. In order to meet the recommended daily protein intake (DRIs), lysine-free amino acid formulas were provided additionally: Glutarex (Abbott) (patients #1, 2, 7) and Lys2-prima (Milupa) (patients [3] [4] [5] [6] . Glutarex is free of lysine and tryptophan, whereas Lys2-prima contains 1.3 g of tryptophan per 100 g. Tryptophan supplements (20 mg/kg/day) were provided to patients receiving Glutarex to meet the DRIs for this amino-acid [8, 9] .
Monitoring and outcome assessment during the lysine-restricted diet
All patients underwent vision and hearing tests prior to starting dietary treatment to rule out sensory deficits as cause of developmental delay. Samples for plasma amino-acids were collected in a fasting state (minimum 3 h) every 3 months. Samples for plasma pipecolic acid were collected in a 4-6 h fasting state for patients #1 and #2 and less than 4 h for patients #3-7. Urinary AASA was measured in samples collected after overnight sleep For patients #1 and #2, a monitoring protocol was implemented that included the following investigations every 3 months: clinical and neurological assessments (somatic growth parameters) as well laboratory testing for nutritional parameters, including pre-albumin, albumin, complete blood cell count and iron status.
Electroencephalogram (EEG) was performed during clinic visits (every 3-6 months). Cerebrospinal fluid (CSF) samples for measuring amino acids and AASA were collected for patients 1 and 2 while they were under sedation for MRI/spectroscopy brain scan. Nerve conduction studies were performed in patient #2 while on high pyridoxine dosage (40 mg/kg/day).
Developmental assessments were performed with tests routinely used at the collaborating centers. These included the Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III); Gesell Developmental Assessment; the Denver Developmental Screening Test; the Peabody Motor Scales II; the Wechsler Intelligence Scale For Children (WISC-IV); Pre-School Language Scale-4th ED; Clinical Evaluation of Language Fundamentals (CELF-IV); the Kaufman Assessment Battery for Children, 7th German Ed (K-ABC); and the Snijders-Oomen Non-Verbal Intelligence Test (Revised) 5.5-17 years (SON-R 5.5). Parental observations regarding their children's behavior, well-being, and developmental progress were also included as non-objective outcome parameters.
Chemical biomarkers
To determine the effects of treatment, plasma pipecolic acid was measured in all patients, urine AASA (frozen shipments) in patients #1-6, and plasma AASA in patient #7. For patients #1 and #2, plasma pipecolic acid was measured at Kennedy Krieger Institute in Baltimore, USA (method: Kok et al. [10] ). For patients #3, #4, and #5, plasma pipecolic acid was initially measured at University Hospital in Graz, Austria (method: Kelley et al. [11] ) and along with patient #6 from September 2009 onwards at the VU Medical Center, Amsterdam (Kok et al. [10] ). Urine AASA was measured for patients #1-6 at the VU Medical Center, Amsterdam (methods: Struys et al. [12] ) For patient #7, plasma AASA and P6C was measured at Seattle Children's Research Institute, Seattle (method: Sadilkova et al. [13] ) and plasma pipecolic acid at Mayo Medical Laboratories, Rochester (Kok et al. [10] ). For patients #1, #2 and #7, biomarkers were measured in CSF samples at the VU Medical Centre, Amsterdam (method: Mills et al. [14] ). The reduction of metabolites was calculated using the last value prior to and first value after initiation of dietary lysine restriction (values expressed as X-fold increase of the upper limit of normal value age related controls).
Ethics approval
For patients #1 and #2, this study was approved as an "innovative treatment protocol" by the British Columbia Children's Hospital Review Board. For patients #3, #4, #5, and #6 approval was obtained from the Ethics Review Board at Hannover Medical School. For patient #7, the treatment was performed as part of clinical care and the patient was enrolled in a Colorado Multiple Institutional Review Board approved research protocol. Parents provided written consent for publication of the study results.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Diagnosis was established at a median age of 6 weeks (range 0.5-5 months) during the period 1999 and 2011, based on clinical presentation of neonatal or infantile onset of epileptic seizures and response to pyridoxine therapy, with subsequent confirmation through demonstration of elevated urinary AASA and/or plasma pipecolic acid levels and at least one disease-causing sequence change in the ALDH7A1 gene. The clinical follow-up varied in duration between 4.0 months and 12.1 years (mean 7.1 years) from age of clinical presentation to the most recent clinic visit in 2012. Adjunctive dietary lysine restriction was initiated at a median age of 3.6 years (range 1 month-11.8 years) for a period varying from 6 months to 4.2 years. The total duration of treatment with dietary lysine restriction was 140.8 months.
Chemical biomarker results
Lysine restriction resulted in a reduction of all measured chemical biomarkers, including plasma lysine (9.5-58.9%), plasma pipecolic acid (26.0-67.0%) in patients #1-7; urinary AASA levels (13.0-72.0%) in patients #1, 2, 3, 5, and 6; CSF AASA (81.7%) and CSF pipecolic acid (87.2%) in patient #2; plasma AASA level (45%) and plasma P6C (42%) in patient #7. Figs. 2 to 8 show this trend for the individual patients as profile plots for the entire study duration.
In the CSF of patient #1, obtained at age 2.3 years, after 17 months of dietary therapy, the AASA measured 1.9 μmol/l (reference range 0-0.1); pipecolic acid 0.57 μmol/l (reference range 0.009-0.12); lysine 8.1 μmol/l (reference range 5.9-37.1). For patient #2 (described in more detail by Gallagher et al. [3] , prior to lysine restriction at age 4.5 months, CSF AASA measured 8.2 μmol/l, CSF pipecolic acid 3.0 μmol/l, CSF lysine 16.8 μmol/l. At age 4.6 years after 13 months of diet, CSF AASA measured 1.5 μmol/l, CSF pipecolic acid 0.39 μmol/l, CSF lysine 11.2 μmol/l (same reference ranges as noted for patient 1). For patient #7, the CSF AASA obtained at age 3 months (after 2 months of dietary therapy), AASA measured 0.5 μmol/l (reference range 0-0.1). For the remaining patients, CSF biomarker measurements were not performed.
Safety
Nutritional status and somatic growth remained within normal limits for all patients throughout the dietary period; no adverse effects were reported. Plasma lysine levels remained within the lower ageadjusted normal range. Tryptophan levels remained within normal limits (data not shown). Further nutritional parameters in blood remained normal, as did somatic growth and well-being (data not shown).
Clinical outcomes
Patient #1 presented with neonatal epileptic encephalopathy, hypoglycemia, lactic acidosis, and MRI abnormalities [15] . She became clinically seizure free on pyridoxine and folinic acid therapy at age 6.5 weeks with abnormal EEG which normalized at age 6 months. After 2 years of dietary treatment neurodevelopmental testing showed improvement of fine and gross motor skills. Frequent spike waves without clinical correlate on EEG at age 3 years were attributed to neonatal hypoglycemia and cerebral hemorrhages. Pyridoxine dose was increased from 15 to 30 mg/kg/day, with pending EEG follow-up. Patient #2 presented at age 2 months with focal clonic seizures treated with a loading dose of phenytoine and maintenance pyridoxine, folinic acid and phenobarbital (latter stopped at age 1.5 years). Triggered by fever or missed medication, seizures with abnormal EEG continued despite high dose pyridoxine (40 mg/kg/day). At age 3 years, he showed electrophysiological evidence of sensorimotor neuropathy and moderate global developmental delay. Dietary lysine restriction was initiated at age 3.5 years, with subsequent cessation of clinical seizures and normalization of the EEG, allowing a decrease of pyridoxine dosage to 20 mg/kg/day. Also, developmental and behavioral improvement was observed with age-appropriate test results in all domains except for mild expressive speech delay. When the diet was shortly interrupted due to adherence problems, he experienced a relapse of seizures with Todd's paresis and a behavioral deterioration. Most recently at age 6.5 years, with clobazam started and folinic acid stopped in the meantime, he experienced rare unprovoked focal seizure with EEG deterioration, upon which folinic acid was restarted. Patient #3 suffered neonatal seizures, poorly controlled seizures on and off Phenobarbital. She became seizure free when pyridoxine (10 mg/kg/day) was started at 4 months of age. She attended a special school for children with speech delay. Six months after the lysine restriction was started at age 11.9 years, the diet was stopped as parents did not note significant improvement of her speech and she Fig. 3 . Patient #2 showed an 50% reduction of urine AASA (32 to 16 fold decrease from upper limit normal), a 27% reduction and normalization of plasma pipecolic acid (1.8 to 1.3 fold decrease from upper limit normal), a 81.7% reduction of CSF AASA (82 to 15 fold decrease from upper limit normal), and a 87.2% reduction of CSF pipecolic acid (25 to 3.2 fold decrease from upper limit normal), all defined as the difference between last value before and first value after initiation of lysine restriction.
Fig. 2.
Line graph depicting change in biochemical markers (y-axis) before and after dietary therapy was initiation as function of age (x-axis). Urine AASA (mmol/mol creatinine) and plasma pipecolic acid (µmol/L) are expressed as absolute values. Patient #1 showed a 72% reduction of urine AASA (22 to 6 fold decrease from upper limit normal) and a 55% reduction of plasma pipecolic acid (2 to 0.9 fold decrease from upper limit normal), both defined as the difference between last value before and first value after initiation of lysine restriction.
developed a strong desire for animal protein. Biomarkers returned to pre-treatment levels. Patient #4 was born at 33 +3 gestational weeks, and presented with neonatal seizures and lactic acidosis. She has remained seizure-free on pyridoxine mono-therapy. Dietary lysine restriction was started at age 5.5 years and impressive clinical developmental progress (pre-diet IQ 70) was observed, especially regarding speech and language; formal testing is pending. Patient #5 presented with neonatal seizures, and remains seizure free upon pyridoxine mono-therapy. Dietary lysine restriction was started at 4.5 years, and she showed impressive progress of grossly delayed motor and language skills. Patient #6 was seizure free on pyridoxine, started at age 6 weeks. At 4 months, dietary lysine restriction and folinic acid were initiated when she was weaned off breast milk and phenobarbital was stopped. At age 9 months, she suffered a generalized tonic-clonic seizure during an infection, but EEG was normal. At age 10 months, developmental testing showed an overall improvement of motor skills and communication, from moderately to mildly delayed. Patient #7 presented on the 9th day of life with vomiting, lethargy, hypoglycemia and therapy-resistant seizures with a 'near burst suppression' pattern on EEG. After 2 days, she responded after 2 days to pyridoxine with resolution of seizures and normalization of the EEG. Since initiation of diet at 4 weeks (reducing the calculated cerebral lysine influx from 8.6 to 4.9 nmol/min/g brain [16] ), she has remained seizure free and is developmentally age-appropriate on clinical exam.
Discussion
First proof of principle
This article is the first to report on the biochemical and clinical results of dietary lysine restriction as adjuvant therapy for PDE due to ATQ deficiency. The fact that 75-80% of patients suffer global Fig. 4 . Patient #3 showed a 13% reduction of urine AASA (7.6 to 4 fold decrease from upper limit normal) and a 60% reduction and normalization of plasma pipecolic acid later (2 to 0.8 fold decrease from upper limit normal), both defined as the difference between last value before and first value after initiation of lysine restriction. Fig. 5 . Patient #4 showed a 68.5% reduction of urine AASA (14 to 4.4 fold decrease from upper limit normal) and a 56% reduction of plasma pipecolic acid (3 to 1.3 fold decrease from upper limit normal), both defined as the difference between last value before and first value after initiation of lysine restriction.
developmental delay or intellectual disability (IQ b 70) despite adequate seizure control by pyridoxine treatment [4, 5, 16] illustrates the need for additional therapeutic strategies in PDE. Extrapolating experience from other neurotoxic inborn errors of metabolism, early intervention with dietary therapy is a beneficial approach to prevent brain damage and optimize neurodevelopment.
In our cohort, dietary lysine restriction effectively reduced chemical biomarkers. Patient #2 showed a significant reduction of CSF AASA as well as pipecolic acid. This observation is important, as the brain is the main pathophysiological target in ATQ deficiency. However, we cannot exclude that a proportion of this decrease may result from the folinic acid treatment itself, in view of the case reported by Hyland et al., showing a 75% reduction of the 'unknown peak' on monoamine analysis (likely related to AASA metabolism) with age and on folinic acid therapy [17] . The observed reduction of urinary AASA is in agreement with the published correlation of protein intake and urinary AASA excretion in neonates [12] . Urinary AASA and plasma pipecolic acid concentrations decline with age in healthy controls [10] , and upon pyridoxine treatment in PDE [18, 19] . With dietary restriction, we observed a further decline of these biomarkers in all but one patient (#5 in whom pre-diet samples were lost), and most notably normalization of urinary AASA in patient #1.
The data on patients #6 and #7 demonstrate that concomitant dietary lysine restriction with introduction of solid food in early infancy is welltolerated and also results in a remarkable decrease of plasma and urinary biomarkers. For patient #7 the calculated cerebral lysine flux after institution of dietary therapy is similar to that reported in Glutaric Aciduria I patients [20] . These data provide proof of principle that reducing the flux through the lysine degradation pathway will lower the accumulation of potentially neurotoxic substrates arising from the enzymatic block.
The clinical impact of this treatment intervention is more difficult to quantify but seems promising: Up to 10% of patients with PDE have incomplete seizure control with pyridoxine mono-therapy, as in patient #2, seizures persisted despite high dosages of pyridoxine. Dietary lysine restriction resulted in seizure control allowing reduction of pyridoxine dosage; relapse of seizures during brief interruption of the diet illustrates a relation of cause and effect. His recent seizure at age 6.5 years is most likely due to cessation of folinic acid by mother. Patient #6, having been Fig. 6 . Patient #5 showed a 67% reduction of plasma pipecolic acid (3.4 to 1.1 fold decrease from upper limit normal), defined as the difference between last value before and first value after initiation of lysine restriction. Urine AASA values are only available during the period after dietary restriction was started. Fig. 7 . Patient #6 showed a 63% reduction of urine AASA (23 to 8.5 fold decrease from upper limit normal) and a 20% reduction of plasma pipecolic acid (5 to 4 fold decrease from upper limit normal), both defined as the difference between last value before and first value after initiation of lysine restriction. seizure free for 6 months on pyridoxine and Phenobarbital, suffered a convulsion during a febrile illness 5 months following lysine restriction and 1 month after Phenobarbital was discontinued. The remaining patients remained seizure-free upon diet and vitamin B6.
Developmental progress was reported in 4 out of the 5 patients showing delayed development before initiation of dietary therapy; confirmation with formal assessment was possible in 3 patients. The most pronounced improvements were observed in patients #2 and #5.
As in patients #6 and #7, lysine restriction was introduced in early infancy; it will not be possible to delineate the influence of this adjuvant treatment on their development.
Limitations
This is an observational study about the feasibility and safety of dietary lysine restriction as adjuvant treatment in PDE. As in all rare diseases, we have to accept certain limitations that need to be taken into account with regards to the interpretation of these study results:
(1) Chemical markers: The patients cover a wide age range. It is well known that during the first year of life, metabolites of lysine degradation decrease significantly in PDE patients [18, 19] . We tried to control for this by expressing the data as X-fold increase of the upper limit of normal value of age related controls. Biochemical analyses were performed by different laboratories applying slightly different methodology. However, in view of the large changes we observed with lysine restriction, the small differences between the respective normal values are insignificant. (2) Seizure control: In PDE, the optimal pyridoxine dosage required to achieve seizure control is not known and different therapeutic strategies are followed at different institutions. Consequently, the vitamin B6 dosage varied between our patients, but remained unchanged during dietary treatment, as is true for the additional folinic acid therapy in 2 patients. Patients #2 and #6 received anticonvulsive treatment, which was weaned after initiation of lysine restriction. (3) Developmental outcome evaluation: Due to the wide age range of our patients and to the varying potential of the institutions involved, a large number and wide range of developmental tests (n=8) were applied for assessment of neurodevelopmental outcome in 7 patients. The judgment of parents and investigators on children's developmental progress is prone to bias, but all families except for the family of patient #3 opted to continue the diet in spite of the well-known burden of protein limitation.
To address these limitations, a standard protocol and guidelines have been developed to evaluate the effect of lysine restricted diet for all future studies.
Need for more evidence
Due to these limitations and the nature of the study, the evidence level for the effects of this treatment is 4 according to the Centre for Evidence-based Medicine criteria [21] . This situation is inherent for rare inborn errors of metabolism. In a systematic literature review [22] , we identified 81 treatable inborn errors of metabolism causing intellectual disability, of which ATQ deficiency is one. For the majority Fig. 8 . Patient #7 showed an 45% reduction of plasma AASA (11 to 6 fold decrease from upper limit normal), a 50% reduction of plasma pipecolic acid (6 to 3 fold decrease from upper limit normal), and a 42% reduction of plasma P6C (19 to 11 fold decrease from upper limit normal), all defined as the difference between last value before and first value after initiation of lysine restriction. (79%) of the 91 treatments identified, the evidence level ranks 4 or lower. Still, 60% of these therapeutic modalities are considered as "standard of care".
Dietary lysine restriction for ATQ deficiency places a burden on patients and their families, and they often conflict with social and cultural traditions [23] . Also, this diet requires monitoring by a specialist and metabolic dietician or nutritionist with regular laboratory testing and clinical follow-up. Finally, more data are needed to predict which patients with ATQ deficiency will benefit from additional dietary lysine restriction, as natural history data indicate that up to 20% of patients with PDE may show normal psychomotor development on pyridoxine therapy. Thus, before this potentially burdensome dietary intervention becomes mainstay treatment, to further document potential benefits a multicenter prospective study on short-and long-term outcomes of a lysine restricted diet as adjunctive therapy in ATQ deficiency is warranted. Additionally one could consider addition of arginine to the lysine-restricted formula, to exploit the transport competition between lysine and arginine over the blood-brain barrier and further reduce cerebral lysine flux. A similar treatment strategy has shown promising preliminary results in glutaric aciduria type I [24] .
International PDE consortium and research framework
As a first approach to improve evidence, an international consortium of leading clinicians and scientists with experience in PDE and ATQ deficiency developed a protocol for dietary lysine restriction and subsequent monitoring of safety and efficacy.
Randomized controlled trials are the gold standard to create high levels of evidence for treatments. However in rare diseases there are considerable methodological, logistic, and financial limitations to establish such trials. In order to overcome these roadblocks, we are suggesting the simultaneous use of different study designs including N-of-1 trials as well as observational controlled cohort designs, allowing inclusion of all patients, irrespective of age, severity, symptoms, and interventions. Fig. 9 shows how such an integrated approach allows generation of high evidence levels. The website www.pdeonline.org comprises an easy to use 'methodological toolbox' with different study designs & protocols. Also, it provides access to a registry for physicians, scientists, and families who wish to participate in any research on PDE. This novel research framework will enable physicians to provide the highest quality of care while using new media to connect people around the world and help generate a strong level of evidence for treatment of ATQ deficiency. We will use this study to build a model framework to study therapeutic interventions in this and other rare genetic conditions, aimed to improve evidence for treatments and outcomes of affected patients.
